Sugi Predict

Sugi Predict / Compounds / SCHEMBL2265054

SCHEMBL2265054

SCHEMBL2265054

CN(C)C(=O)c1cccc(C=O)c1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ UNG P13051 1/20 0.61
▸ ERN1 O75460 8/20 0.55
▸ TRIM24 O15164 1/20 0.45
▸ TRIM33 Q9UPN9 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PMM2 O15305 1/20 0.40
▸ MPI P34949 1/20 0.40
▸ PHOSPHO1 Q8TCT1 1/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ LOX P28300 1/20 0.39
▸ CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968407 1.00 UNG (0.61) UNGERN1TRIM24TRIM33ALDH1A1
SCHEMBL27554713 0.85 ERN1 (0.48) UNGERN1ALDH1A1MEN1KMT2A
SCHEMBL18774069 0.84 ERN1 (0.47) UNGERN1ALDH1A1MEN1KMT2A
SCHEMBL30037936 0.83 UNG (0.54) UNGERN1TRIM24TRIM33ALDH1A1
SCHEMBL7406706 0.82 MEN1 (0.55) ERN1ALDH1A1MEN1KMT2APMM2
SCHEMBL4488272 0.81 HPGD (0.63) UNGALDH1A1HPGDSMN1; SMN2
SCHEMBL15768190 0.80 UNG (0.51) UNGERN1TRIM24TRIM33MEN1
SCHEMBL4576119 0.80 UNG (0.47) UNGERN1
SCHEMBL27878808 0.80 UNG (0.55) UNGERN1TRIM24TRIM33ALDH1A1
SCHEMBL3936180 0.80 NPSR1 (0.54) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170117-A1 MODULATORS OF ACKR3 AND USES THEREOF INTERAX BIOTECH AG (CH) 2025-05-29 — — US disclosed
EP-4486739-A1 MODULATORS OF ACKR3 AND USES THEREOF InterAx Biotech AG (CH) 2025-01-08 — — EP disclosed
US-20240059658-A1 QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER UNIV EMORY (US) 2024-02-22 — — US disclosed
WO-2023166190-A1 MODULATORS OF ACKR3 AND USES THEREOF INTERAX BIOTECH AG (CH) 2023-09-07 — — WO disclosed
EP-4238970-A1 MODULATORS OF ACKR3 AND USES THEREOF InterAx Biotech AG (CH) 2023-09-06 — — EP disclosed
WO-2021050721-A1 QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER EMORY UNIVERSITY (US) 2021-03-18 — — WO disclosed
WO-2021050721-A1 QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER EMORY UNIVERSITY (US) 2021-03-18 — — WO disclosed
US-9931327-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-04-03 — — US disclosed
US-9931327-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-04-03 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-20130005716-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-01-03 — — US disclosed
US-20130005716-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-01-03 — — US disclosed
US-8003649-B2 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 ASTRAZENECA AB (SE) 2011-08-23 — — US disclosed
EP-2235010-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS AstraZeneca AB (SE) 2010-10-06 — — EP disclosed
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 ASTRAZENECA AB (SE) 2010-01-21 — — US disclosed
WO-2009081197-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed
WO-2009066084-A1 2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-05-28 — — WO disclosed
EP-2044063-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER Astra Zeneca AB (SE) 2009-04-08 — — EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170117-A1 MODULATORS OF ACKR3 AND USES THEREOF ACKR3, PROKR2, PROKR1 UNG 4611/4885ERN1 3159/4885TRIM24 3667/4885
US-20240059658-A1 QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER MDM2, TP53, RECQL UNG 392/4885ERN1 4279/4885TRIM24 1470/4885
US-20130005716-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE12 UNG 626/4885ERN1 1884/4885TRIM24 902/4885
US-20100016279-A1 BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 AR, NR5A1, CYP17A1 UNG 3033/4885ERN1 3859/4885TRIM24 3249/4885
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 UNG 4739/4885ERN1 2355/4885TRIM24 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.